Shiseido to Sell Aupres Owner SLC to IDG-Led Consortium

The binding deal would transfer the China-based cosmetics unit and its Beijing factory as Shiseido focuses on higher-growth priorities.

Shiseido has agreed to sell its Chinese subsidiary, Shiseido Liyuan Cosmetics (SLC), to an investor consortium led by Hong Kong-based private equity firm IDG Capital. The unit makes and sells the Aupres brand in China, and the Japanese cosmetics group has signed a binding agreement to transfer all of the company.

The deal is expected to close between the fourth quarter of 2026 and the first quarter of 2027, subject to regulatory approvals, including in China. Financial terms were not disclosed.

A profitability and focus decision

Shiseido framed the sale as part of its 2030 Medium-Term Strategy, which aims to improve profitability and capital efficiency. The group said it wants to drive sustainable growth and strengthen its competitiveness in China by concentrating management resources on areas where it enjoys the greatest competitive advantage.

SLC requires continued investment in product innovation and digital capabilities, according to Shiseido. The divestment is intended to allow the group to concentrate on priority brands and higher-growth opportunities. Shiseido also described China as a strategically important and attractive market where e-commerce is expanding rapidly, consumer behavior is changing and diverse market participants are emerging.

Ownership and transition terms

Under the transaction, funds managed by IDG Capital will take 95% of the equity through two special purpose vehicles. A limited partnership enterprise set up mainly by SLC's new management team will hold the remaining 5%. The deal includes SLC's Beijing factory and production equipment.

Shiseido said it believes independent operation under IDG will support SLC's sustainable growth and brand value. To ensure a smooth handover, Shiseido will license the intellectual property rights IDG needs to run the business. For a specified period after the transfer, Shiseido will also provide support on new product development, technical assistance for the stable supply of existing products, and continued supply of raw materials and selected products. The transitional collaboration is meant to maintain SLC's innovation capabilities, product quality and business continuity.

From joint venture to full ownership and sale

SLC was established in 1991 as a joint venture with Beijing Liyuan, a subsidiary of Yiqing Group owned by the Beijing Municipal Government. It has sold the C-beauty brand Aupres since 1994. With the current joint venture agreement due to expire in December 2026, the parties agreed not to renew it. On September 1, 2026, Shiseido acquired Beijing Liyuan's 35% stake, giving it full ownership ahead of the now-announced sale.

Profit recovery provides the backdrop

The divestment comes days after Shiseido reported a 124.3% jump in core operating profit for the third quarter of 2026, to ¥67.5 billion, or US$422.13 million. The company attributed the recovery to restructuring, cost cuts and improved margins rather than strong product demand; like-for-like sales grew 0.7%. Shiseido raised its full-year core operating profit forecast from ¥59 billion, or US$433 million, to ¥87 billion, or US$546 million.

The sale would reduce Shiseido's direct ownership of the Aupres business while preserving licensing and supply links during the transition. Completion still depends on approvals, and the terms of the licensing and supply arrangements beyond the specified support period were not disclosed.

LN

Linnea Nordvik

Linnea Nordvik covers beauty mirrors, salon devices, makeup brushes, lashes, and beauty tools as a salon equipment and tools writer focused on material behavior and maintenance. Her evidence reviews specify CRI, correlated color temperature, illuminance, glare conditions, brush fiber density, handle pull force, and adhesive compatibility without treating any sample as universally safe or compliant. She helps salon operations managers, retail buyers, and product development teams compare equipment specifications, cleaning protocols, and supplier documentation while avoiding medical device claims and personal beauty advice.